Compare

60 Degrees Pharmaceuticals, Inc. vs Dare Bioscience, Inc. vs China SXT Pharmaceuticals, Inc. vs Longeveron Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year60 Degrees Pharmaceuticals, Inc.
SXTP
Dare Bioscience, Inc.
DARE
China SXT Pharmaceuticals, Inc.
SXTC
Longeveron Inc.
LGVN
Year ended2025-12-312025-12-312026-03-312025-12-31
Revenue$1.01M$1.03M$1.14M$1.20M
Revenue growth (YoY)+65.5%n/m-34.6%-49.9%
Gross margin22.3%71.3% (computed)21.9%67.0%
Operating margin-771.6%n/m-625.9%n/m
Net margin-732.5%n/m-545.2%n/m
Net income-$7.37M-$13.40M-$6.21M-$22.70M
EPS (Diluted)-$11.73-$1.20-$9.13-$1.29
Operating cash flow-$6.85M-$9.90M-$4.02M-$18.64M
Free cash flow-$6.99M-$10.29Mn/a-$18.89M
Cash & equivalents$1.51M$24.71M$28.18M$4.66M
Total assets$5.37M$32.47M$34.75M$10.26M
Total liabilities$1.99M$29.63M$5.05M$4.59M
Shareholders' equity$3.46M$2.84M$29.71M$5.67M
Return on year-end equity-212.7%-471.4%-20.9%-400.1%
Shares outstanding1.16M14.50Mn/an/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year60 Degrees Pharmaceuticals, Inc.Dare Bioscience, Inc.China SXT Pharmaceuticals, Inc.Longeveron Inc.
Latest$1.01M
Ended 2025-12-31
$1.03M
Ended 2025-12-31
$1.14M
Ended 2026-03-31
$1.20M
Ended 2025-12-31
1 year earlier$607.6K
Ended 2024-12-31
$9.8K
Ended 2024-12-31
$1.74M
Ended 2025-03-31
$2.39M
Ended 2024-12-31
2 years earlier$253.6K
Ended 2023-12-31
$2.81M
Ended 2023-12-31
$1.93M
Ended 2024-03-31
$709.0K
Ended 2023-12-31
3 years earlier$223.2K
Ended 2022-12-31
$10.00M
Ended 2022-12-31
$1.97M
Ended 2023-03-31
$1.22M
Ended 2022-12-31
4 years earliern/a$0
Ended 2021-12-31
$2.60M
Ended 2022-03-31
$1.31M
Ended 2021-12-31